Robert James Wills
Independent Chairman of the BoardDr. Robert James Wills, also known as Rob, B.S. M.S. Ph.D., is Chairman of the Board of Alpha Cognition Inc. from June 2026. Dr. Wills was Independent Director of Alpha Cognition Inc. from April 7, 2025. Dr. Wills served as Non-Independent Director at Oncternal Therapeutics, Inc. since June 2019 until July 2025. Dr. Wills has experience as a leader in the pharmaceutical industry. Dr. Wills has been Independent Chairman of the board at Milestone Pharmaceuticals Inc since January 1, 2021. He is an Independent Non Executive Director of Milestone Pharmaceuticals Inc since October 1, 2020. Dr. Wills was Executive Chairman of GTX Inc. since March 02, 2015. Dr. Wills served as Senior Vice President of Global Development at J&J. He is Director of Feldan Therapeutics and also has been it's Scientific Advisory Board Member since January 2021. Dr. Wills was responsible for its late stage development pipeline. He has been a Senior Advisor to GO Therapeutics since June 2015. Dr. Wills served in a variety of executive roles for Johnson & Johnson, or J&J, a medical device, pharmaceutical and consumer goods manufacturing company, from December 1989 to February 2015. Dr. Wills is an accomplished, seasoned senior executive career spans directing R&D, business development and alliance management for major pharmaceutical firms. At Johnson & Johnson (J&J), Dr. Wills served as Vice President, Alliance Manager and was responsible for managing strategic alliances for the Pharmaceutical Group worldwide since 2002. He was Vice President, Alliance Management, Janssen Pharmaceutical Companies of Johnson & Johnson. He Prior to this, Dr. Wills worked in pharmaceutical drug development, 12 of which were at Johnson & Johnson and 10 at Hoffmann-LaRoche. He served as Independent Chairman of Cymabay Therapeutics, Inc. since October 6, 2015 until March 22, 2024. He has been Director at Parion Sciences, Inc. since March 15, 2016. He has been a Director of GO Therapeutics Inc. since October 2017. He is a member of the Emerging Companies Section Governing Board of Biotechnology Innovation Organization (BIO). He served as Independent Director of Cymabay Therapeutics, Inc. since March 18, 2015 until March 22, 2024. He was a member of several internal commercial and research and development operating boards. Dr. Wills holds a B.S. in Biochemistry and an M.S. in Pharmaceutics from the University of Wisconsin and a Ph.D. in Pharmaceutics from the University of Texas.
Positions
- Company NameAlpha Cognition Inc.Stock CodeACOGPositionIndependent Chairman of the BoardColleagues
- MEMichael E. McFaddenCEO & Director
- RJRobert James WillsIndependent Chairman of the Board
- KAKenneth Anthony CawkellFounder, Consultant, Corporate Secretary & Director
- HHHenry H. DuVP of Finance & Accounting and Interim CFO
- LDLauren D’AngeloChief Operating Officer
- DGDenis G. KayChief Scientific Officer
- PMPhillip MertzIndependent Director
- RKRajeev K. BakshiIndependent Director
- Company NameMilestone Pharmaceuticals Inc.Stock CodeMISTPositionIndependent Chairman of the BoardColleagues
- JGJoseph G. OlivetoCEO, President & Executive Director
- AHAmit HasijaCFO & Executive VP of Corporate Development
- DBDavid B. BharuchaChief Medical Officer
- PDPhilippe DouvilleFounder, Strategic Advisor & Member of Scientific Advisory Board
- JNJeffrey NelsonChief Operating Officer
- PTPhilip T. SagerChief Medical Advisor & Member of the Scientific Advisory Board
- MJMichael John TomsicekIndependent Non-Executive Director
